Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Boehringer Ingelheim. (1/17/19). "Press Release: Boehringer Ingelheim Biopharmaceuticals China Expands Commercial Manufacturing Capacities". Shanghai.

Region Region Shanghai
  Country China
Organisations Organisation Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. (BI BioChina)
  Group Boehringer Ingelheim (Group)
  Organisation 2 Boehringer Ingelheim (Group)
Products Product contract manufacturing (biologicals)
  Product 2 biopharmaceutical
Persons Person Luo, Jiali (Boehringer 201801 General Manager of Boehringer Ingelheim Biopharmaceuticals (China) Co Ltd)
  Person 2 Buecheler, Uwe (Boehringer 201901 Head of Biopharmaceutical Business Unit)

> Expansion of manufacturing capacities in OASIS facility

> Increasing demands for world-class manufacturing in Shanghai, China

> First commercial product manufacturing in Shanghai expected in 2019

Boehringer Ingelheim announced today that it has initiated a capacity expansion at its commercial manufacturing site for biologics in China. The expansion covers an additional bioreactor and includes all needed utility and infrastructure to support the GMP operations of 2x 2.000L single use bioreactor manufacturing lines.

‘We are fully committed to our biopharmaceutical contract manufacturing business in China and it is our utmost goal to serve our customers and their patients with high quality medicines in China and in the global market’, said Prof. Dr. Buecheler, Head of Biopharmaceutical Business Unit at Boehringer Ingelheim.

Boehringer Ingelheim’s biopharmaceutical contract manufacturing business is expected to begin manufacturing the commercial supply of a monoclonal antibody out of its China manufacturing OASIS facility in 2019. This will be the first commercial drug manufactured in the Shanghai facility, OASIS, an important part of Boehringer Ingelheim’s global biopharmaceutical production network. Following the commercial manufacturing of a client’s antibody, a number of investigational drugs are in Boehringer Ingelheim’s contract manufacturing business pipeline for potential future market launch and commercial supply out of Shanghai, China.

‘We look forward to providing our customers with this new source of commercial supply of therapeutic antibodies for their patients,’ states Dr. Jiali Luo, General Manager and Site Head of Boehringer Ingelheim Bio China. ‘Additionally, we see a growing demand for world-class manufacturing capacities of biologics and are eager to offer our capabilities to local and global customers according to our site supply mission “China-for-China” and “China-for-Global” ’.

About Boehringer Ingelheim Biopharmaceuticals China

As one of the world’s largest biopharmaceutical producers, Boehringer Ingelheim is China’s first international provider of biopharmaceutical contract manufacturing solutions with all-round services, including process development and product supply for clinical trials and market, to its clients in China and all over the world. Boehringer Ingelheim Biopharmaceuticals (China) Ltd.’s facility was officially put into operation in May 2017. As the first and only biopharmaceuticals facility in line with global standards set by a multinational pharma company in China, the facility has become a major milestone in Boehringer Ingelheim’s’ strategic blueprint for its biopharmaceuticals business globally.

About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on or in our annual report:

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Media Contact

Matthias Reinig
Media Contact - Corporate Topics
Media + PR
Phone +49 6132 77 184855
Mobile +49 151 15971354
Fax +49 6132 77 6601
› E-mail
Binger Strasse 173
55216 Ingelheim am Rhein GERMANY

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Boehringer Ingelheim (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top